The english version of the website of the School of Medicine is under development

Δημοσίευση

Pharmacotherapy of obesity: Available medications and drugs under investigation.

TitlePharmacotherapy of obesity: Available medications and drugs under investigation.
Publication TypeJournal Article
Year of Publication2019
AuthorsPilitsi, E., Farr O. M., Polyzos S. A., Perakakis N., Nolen-Doerr E., Papathanasiou A-E., & Mantzoros C. S.
JournalMetabolism
Volume92
Pagination170-192
Date Published2019 Mar
ISSN1532-8600
Abstract

Obesity is a chronic disease with a continuously rising prevalence that currently affects more than half a billion people worldwide. Energy balance and appetite are highly regulated via central and peripheral mechanisms, and weight loss triggers a homeostatic response leading to weight regain. Lifestyle and behavioral modifications are the cornerstones of obesity management; however, they often fail to achieve or sustain long-term weight loss. Pharmacotherapy added onto lifestyle modifications results in an additional, albeit limited, weight reduction. Regardless, this weight reduction of 5-10% conveys multiple cardiovascular and metabolic benefits. In this review, evidence on the food and drug administration (FDA)-approved medications, i.e., orlistat, lorcaserin, phentermine/topiramate, liraglutide and naltrexone/bupropion, is summarized. Furthermore, anti-obesity agents in the pipeline for potential future therapeutic use are presented.

DOI10.1016/j.metabol.2018.10.010
Alternate JournalMetab. Clin. Exp.
PubMed ID30391259

Contact

Secretariat of the School of Medicine
 

Connect

Schoole of Medicince presence in social networks
Follow Us or Connect with us.